[go: up one dir, main page]

HUE059945T2 - Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok - Google Patents

Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok

Info

Publication number
HUE059945T2
HUE059945T2 HUE18836520A HUE18836520A HUE059945T2 HU E059945 T2 HUE059945 T2 HU E059945T2 HU E18836520 A HUE18836520 A HU E18836520A HU E18836520 A HUE18836520 A HU E18836520A HU E059945 T2 HUE059945 T2 HU E059945T2
Authority
HU
Hungary
Prior art keywords
heterocyclic compounds
bicyclic heterocyclic
substituted bicyclic
prmt5 inhibitors
prmt5
Prior art date
Application number
HUE18836520A
Other languages
English (en)
Inventor
Prathap Nair
Ganesh Gudade
Sachin Sethi
Dipak Lagad
Chetan Pawar
Mahadeo Tryambake
Chaitanya Kulkarni
Anil Hajare
Balasaheb Gore
Sanjeev Kulkarni
Milind Sindkhedkar
Venkata Palle
Rajender Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of HUE059945T2 publication Critical patent/HUE059945T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HUE18836520A 2017-12-13 2018-12-13 Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok HUE059945T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721044886 2017-12-13
IN201821024634 2018-07-02
IN201821040029 2018-10-23

Publications (1)

Publication Number Publication Date
HUE059945T2 true HUE059945T2 (hu) 2023-01-28

Family

ID=65036860

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18836520A HUE059945T2 (hu) 2017-12-13 2018-12-13 Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok

Country Status (30)

Country Link
US (2) US11459330B2 (hu)
EP (1) EP3724190B1 (hu)
JP (1) JP7282778B2 (hu)
KR (1) KR102708147B1 (hu)
CN (1) CN111712498B (hu)
AU (1) AU2018385664B2 (hu)
BR (1) BR112020011746A2 (hu)
CA (1) CA3085259A1 (hu)
CL (1) CL2020001576A1 (hu)
CR (1) CR20200263A (hu)
CU (1) CU24621B1 (hu)
DK (1) DK3724190T3 (hu)
ES (1) ES2927860T3 (hu)
GE (1) GEP20227359B (hu)
HR (1) HRP20221207T1 (hu)
HU (1) HUE059945T2 (hu)
IL (1) IL274936B2 (hu)
LT (1) LT3724190T (hu)
MX (1) MX2020006181A (hu)
MY (1) MY199124A (hu)
PE (1) PE20211444A1 (hu)
PH (1) PH12020550881A1 (hu)
PL (1) PL3724190T3 (hu)
PT (1) PT3724190T (hu)
RS (1) RS63623B1 (hu)
SG (1) SG11202004934QA (hu)
SM (1) SMT202200396T1 (hu)
UA (1) UA126349C2 (hu)
WO (1) WO2019116302A1 (hu)
ZA (1) ZA202003528B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
MA53827A (fr) 2018-10-05 2021-09-15 Vertex Pharma Modulateurs de l'alpha -1 antitrypsine
CA3134613A1 (en) * 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CA3141855A1 (en) * 2019-05-30 2020-12-03 Angex Pharmaceutical, Inc. Heterocyclic compounds as prmt5 inhibitors
DK3980417T3 (en) * 2019-06-10 2023-12-18 Lupin Ltd PRMT5-Inhibitorer
BR112022007808A2 (pt) * 2019-10-22 2022-07-05 Lupin Ltd Combinação farmacêutica de inibidores de prmt5
JP2022553376A (ja) * 2019-10-25 2022-12-22 アクセント・セラピューティクス・インコーポレイテッド Mettl3モジュレーター
WO2021086879A1 (en) 2019-10-28 2021-05-06 Tango Therapeutics, Inc. Compounds and methods of use
JP7664248B2 (ja) * 2019-12-03 2025-04-17 ルピン・リミテッド Prmt5阻害剤としての置換ヌクレオシドアナログ
US20220112194A1 (en) * 2020-04-01 2022-04-14 Aligos Therapeutics, Inc. Compounds targeting prmt5
CN115768772A (zh) 2020-04-03 2023-03-07 弗特克斯药品有限公司 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的吡喃并[4,3-b]L吲哚衍生物
CA3179189A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
TW202220970A (zh) 2020-07-31 2022-06-01 美商譚格醫療公司 化合物及使用方法
CN116723843A (zh) 2021-01-19 2023-09-08 鲁宾有限公司 用于治疗和/或预防癌症的sos1抑制剂的药物组合
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251431A1 (en) 2002-07-22 2004-02-09 Cambridge University Technical Services Ltd. Synthesis of discodermolide
WO2005016878A2 (en) 2003-08-13 2005-02-24 Isis Pharmaceuticals, Inc. METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
EP2049490A1 (en) 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parpおよびtank阻害剤としてのキノリノン誘導体
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
US20110237606A1 (en) * 2008-09-26 2011-09-29 Agency Of Science, Technology And Research 3-Deazaneplanocin Derivatives
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
WO2012002577A1 (ja) 2010-06-30 2012-01-05 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
US9084794B2 (en) 2011-08-19 2015-07-21 Glaxosmithkline Intellectual Property (No. 2) Limited Fatty acid synthase inhibitors
JP6182593B2 (ja) * 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
HK1211285A1 (en) 2012-06-08 2016-05-20 吉利德科学公司 Macrocyclic inhibitors of flaviviridae viruses
WO2014008223A2 (en) 2012-07-03 2014-01-09 Glaxosmithkline Llc Fatty acid synthase inhibitors
HUE040323T2 (hu) 2012-12-21 2019-02-28 Epizyme Inc PRMT5-inhibitorok és alkalmazásaik
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP2935243B1 (en) 2012-12-21 2018-03-14 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
JP2016505001A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド Prmt5阻害剤およびその使用
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
US9856218B2 (en) 2013-03-15 2018-01-02 Ohio State Innovation Foundation Inhibitors of PRMT5 and methods of their use
EA033689B9 (ru) 2013-10-10 2020-04-29 Араксис Фарма Ллк Ингибиторы g12c kras
CA2943882A1 (en) 2014-05-22 2015-11-26 F. Hoffmann-La Roche Ag Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives
SI3160958T1 (sl) 2014-06-25 2021-04-30 Glaxosmithkline Intellectual Property Development Limited Kristalinične soli (S)-6-((1-acetilpiperidin-4-il)amino)-N-(3-(3,4- dihidroizokinolin-2(1H)-il)-2-hidroksipropil)pirimidin-4-karboksamida
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2017530940A (ja) 2014-08-04 2017-10-19 エピザイム,インコーポレイティド Prmt5阻害剤およびその使用
EP3189041B1 (en) 2014-09-03 2021-04-28 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US20180010132A1 (en) 2014-09-11 2018-01-11 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
CN107278205A (zh) 2015-02-24 2017-10-20 辉瑞大药厂 用作抗癌药的取代的核苷衍生物
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) * 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
MX2018005967A (es) 2015-11-16 2018-08-29 Araxes Pharma Llc Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos.
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors

Also Published As

Publication number Publication date
US11459330B2 (en) 2022-10-04
IL274936B1 (en) 2023-05-01
GEP20227359B (en) 2022-03-10
EP3724190B1 (en) 2022-07-06
BR112020011746A2 (pt) 2020-11-17
LT3724190T (lt) 2022-10-10
US20210163486A1 (en) 2021-06-03
WO2019116302A1 (en) 2019-06-20
IL274936A (en) 2020-07-30
DK3724190T3 (da) 2022-10-10
CR20200263A (es) 2020-07-26
SMT202200396T1 (it) 2022-11-18
CL2020001576A1 (es) 2020-11-06
CN111712498A (zh) 2020-09-25
JP2021506793A (ja) 2021-02-22
ZA202003528B (en) 2022-05-25
SG11202004934QA (en) 2020-07-29
JP7282778B2 (ja) 2023-05-29
AU2018385664B2 (en) 2022-06-02
KR102708147B1 (ko) 2024-09-19
US20220267339A1 (en) 2022-08-25
PL3724190T3 (pl) 2022-10-31
CU20200051A7 (es) 2021-03-11
ES2927860T3 (es) 2022-11-11
MY199124A (en) 2023-10-17
PT3724190T (pt) 2022-10-03
CN111712498B (zh) 2023-09-29
RS63623B1 (sr) 2022-10-31
UA126349C2 (uk) 2022-09-21
PE20211444A1 (es) 2021-08-05
US11952380B2 (en) 2024-04-09
AU2018385664A1 (en) 2020-07-02
NZ765656A (en) 2025-02-28
MX2020006181A (es) 2020-09-03
KR20200098598A (ko) 2020-08-20
CA3085259A1 (en) 2019-06-20
HRP20221207T1 (hr) 2022-12-09
IL274936B2 (en) 2023-09-01
EP3724190A1 (en) 2020-10-21
CU24621B1 (es) 2022-09-08
PH12020550881A1 (en) 2021-04-05

Similar Documents

Publication Publication Date Title
HUE059945T2 (hu) Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
IL283333A (en) New heterocyclic compounds
LT3710446T (lt) Junginiai, naudingi cdk7 slopinimui
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3684767T3 (da) Heterocykliske forbindelser som pad-inhibitorer
DK3436444T3 (da) Heterocyklisk forbindelse
HUE060256T2 (hu) Heterociklusos vegyületek mint immunmodulátorok
DK3498693T3 (da) Heterocyklisk forbindelse
SG11202005112TA (en) Heterocyclic compounds as prmt5 inhibitors
SI3145929T1 (sl) 5-kloro-2-difluorometoksifenil pirazolopirimidinove spojine, ki so zaviralci janusove kinaze
EP3689879A4 (en) HETEROCYCLIC CONNECTION
EP3768671C0 (en) SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS
HUE037210T2 (hu) Triciklusos heterociklusos vegyületek, mint foszfoinozitid 3-kináz inhibitorok
EP3706747A4 (en) PRMT5 INHIBITORS
HUE057970T2 (hu) Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok
EP3541806A4 (en) HETEROCYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS
EP3706742A4 (en) PRMT5 INHIBITORS
DK3630752T3 (da) Substituerede nitrogenholdige forbindelser
EP3578549A4 (en) Heterocyclic compound
DK3450436T3 (da) Kondenseret heterocyklisk forbindelse
DK3782986T3 (da) Heterocyklisk forbindelse
EP3693368A4 (en) HETEROCYCLIC CONNECTION
EP3660003A4 (en) Heterocyclic compound